November 9th. Transenterix announced financial results and business update for Q3 2017
-The Senhahce robot has been approved by FDA for commercial sales in the U.S
-1 robot sold in Taiwan in Q3 2017
-Commercial infrastructure built in the U.S. - 17 sales representatives in place.
-1 sales pending (pre order issued) in EU - to be booked in Q4
-At least 1 sale expected in the U.S. in Q4
-$100 M cash in bank - enough to keep the company running well beyond 2018